Skip to main content
. 2023 May 26;14:1165759. doi: 10.3389/fimmu.2023.1165759
Allo-HSCT Allogeneic hematopoietic stem cell transplantation
BM Bone marrow
CMV Cytomegalovirus
DSA Donor-directed anti-HLA-specific allo-antibody
EFS Event-free survival
GETH-TC Spanish Group of Hematopoietic Transplant and Cell Therapy
GF Graft failure
GMTH Madrid Group of Hematopoietic Transplant
GVHD Graft-versus-host disease
Haplo-HSCT Haploidentical hematopoietic stem cell transplantation
HCT-CI Hematopoietic stem cell transplant comorbidity index
IVIG Intravenous immunoglobulins
HLA Human leukocyte antigen
MFI Mean fluorescence intensity
MUD HLA-matched unrelated donor
MMUD HLA-mismatched unrelated donor
NRM Non-relapse mortality
OS Overall survival
PBSC Peripheral blood stem cells
SOS sinusoidal obstruction syndrome
TPE Therapeutic plasma exchange
UCB Umbilical cord blood.